Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Innovent Biologics ( (HK:1801) ).
Innovent Biologics announced a significant financial turnaround for the first half of 2025, with a 50.6% increase in revenue to RMB5,953.1 million, driven by strong performance in oncology products and expanded biomedicine offerings. The company reported a substantial improvement in profitability, with IFRS net profit reaching RMB834.3 million and Non-IFRS net profit at RMB1,213.2 million, highlighting operational efficiency and strategic execution.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$109.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biotechnology company incorporated in the Cayman Islands, primarily focusing on the development and commercialization of oncology products and a broad range of biomedicine. The company is committed to dual-engine growth and global innovation, aiming to strengthen its position in the biopharmaceutical industry.
Average Trading Volume: 24,307,698
Technical Sentiment Signal: Buy
Current Market Cap: HK$164B
See more insights into 1801 stock on TipRanks’ Stock Analysis page.